Navigation Links
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
Date:7/9/2012

IRVINE, Calif. and AMSTERDAM, July 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance.

"It is a very exciting time with the recent launch of Agendia's Symphony suite of tests in an FFPE format as well as the ColoPrint recurrence test for stage II colon cancer prognosis and prediction," said Fredenberg. "As a cohesive executive team, we are poised to bring Agendia to the next level."

Fredenberg has more than twenty years of experience with financial management and corporate governance, primarily in the clinical laboratory industry. Previously, Fredenberg was the CFO at US Labs in Irvine, California, which grew from $1 million in revenue to more than $80 million in revenue and was then successfully sold to LabCorp in 2005. Most recently, he has been the CFO at Clarient in Aliso Viejo, California, which has grown to $140 million in revenue and was successfully sold to GE Healthcare in late 2010. Fredenberg holds a Bachelor of Science in Business Administration from California State University, Fullerton, and is a licensed Certified Public Accountant.

"The addition of Glen Fredenberg to our executive team will have a tremendous impact on Agendia and will accelerate our progress in the molecular diagnostics industry," said David Macdonald, CEO of Agendia. "Our team is focused on the commercialization of our current breast and colon cancer Symphony suite of tests as well as the development of our personalized medicine pipeline."

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact: Post+Beam Melissa Hurley Tel: +1 646 442 2773 E-mail: hurley@postandbeam.is  


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. DiversityInc Names Lilly a Top Company for Diversity
3. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
4. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
5. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
6. Bausch + Lomb Names John Barr Global President Surgical
7. Forbes Names Pharmalot, a UBM Canon Pharmaceutical Media Group Brand, as a Top Social Media Influencer
8. Wake Forest Baptist Names President of Piedmont Triad Research Park and Chief Innovation Officer
9. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
10. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
11. MedVantx Names New VP Employer Solutions and Workplace Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology:
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... The Dermatology ... staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa cum laude. ... School Class President. After his residency in St. Louis, Dr. Dunbar moved to New ...
(Date:7/20/2017)... ... 2017 , ... A budget proposal to switch to an alternate consumer price ... (COLA) is a bad deal for older and disabled Americans, says The Senior ... even more slowly than the conventional one that is currently used to determine the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), ... based Health IT business unit of Constellation Inc., a move that will help the ... of operations in St. Louis, the acquisition is expected to help MTS ...
(Date:7/20/2017)... ... , ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the creation ... teacher who was a summa cum laude graduate of Gardner Webb University. She has ... After her retirement from public school, Lynn continued to pursue her love for music ...
(Date:7/18/2017)... ... ... results of an international clinical trial, led in part by a UC Davis School of ... holds promise for a subgroup of patients. , In a paper just published online in ... sites in 18 countries describe the clinical benefit of using the drug ataluren for a ...
Breaking Medicine News(10 mins):